Candida species are found in the normal human flora; however, predisposing factors, such as immunosuppression, intensive care unit stay, and catheter use, may cause progression to disease. Candida glabrata is a rare, but potentially life-threatening, fungal infection. This report describes the case of a 14-month-old male patient who developed Candida glabrata candidemia during hospitalization in the burn ward. The patient was admitted to the hospital with second-degree scald burns comprising 9.5% of the total body surface area. A fever was observed on the third day of hospitalization and empiric intravenous piperacillin-tazobactam therapy was initiated. A blood culture revealed no microorganism. Fluconazole was added to the patient’s therapy on the fifth day of treatment due to yeast reported on a blood culture taken after a recurrence of fever. Laboratory results indicated that the yeast was Candida glabrata and treatment with caspofungin was implemented. A control blood culture was sterile. Candida glabrata is a rare fungal pathogen, however, it can cause severe infection and is resistant to azoles. The classic risk factors of immunosuppression, intensive care unit admission, or catheter administration were not present in this case, yet it should be kept in mind that burn patients are secondarily immunosuppressed and prone to severe infections.
1. Tavanti A, Davidson AD, Gow NA, Maiden MC, Odds FC. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 2005;43:284–92.
2. Nucci M, Queiroz-Telles F, Alvarado-Matute T, Tiraboschi IN, Cortes J, Zurita J, et al. Latin American Invasive Mycosis Network. Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS One 2013;8:e59373.
3. García-Rodríguez J, Cantón E, Pemán J, Alvarez M, Ezpeleta G, Gómez- Nieto A, et al. Age group, geographical incidence and patterns of antifungal susceptibility of Candida species causing candidemia in the Spanish paediatric population. Enferm Infecc Microbiol Clin 2013;31:363–8.
4. Kara A, Devrim İ, Meşe T, Bayram N, Yılmazer M, Gülfidan G. The Frequency of Infective Endocarditis in Candida Bloodstream Infections: a Retrospective Study in a Child Hospital. Braz J Cardiovasc Surg 2018;33:54–8.
5. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133–63.
6. National Center for Injury Preventions and Control. Data and Statistics (WISQARS). Available at: www.cdc.gov/injury/wisqars/index. html. Accessed Oct 30, 2015.
7. Tse T, Poon CH, Tse KH, Tsui TK, Ayyappan T, Burd A. Paediatric burn prevention: an epidemiological approach. Burns 2006;32:229– 34.
8. Saeman MR, Hodgman EI, Burris A, Wolf SE, Arnoldo BD, Kowalske KJ, et al. Epidemiology and outcomes of pediatric burns over 35 years at Parkland Hospital. Burns 2016;42:202–8.
9. Ramirez-Blanco CE, Ramirez-Rivero CE, Diaz-Martinez LA, Sosa- Avila LM. Infection in burn patients in a referral center in Colombia. Burns 2017;43:642–53.
10. Greenhalgh DG. Sepsis in the burn patient: a different problem than sepsis in the general population. Burns Trauma 2017;5:23.
11. Alangaden GJ.Nosocomial fungal infections: epidemiology, infection control, and prevention. Infect Dis Clin North Am 2011;25:201–25.
12. Hope W, Morton A, Eisen DP. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect 2002;50:56–65.
13. Gupta N, Haque A, Lattif AA, Narayan RP, Mukhopadhyay G, Prasad R. Epidemiology and molecular typing of Candida isolates from burn patients. Mycopathologia 2004;158:397–405
14. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky- Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62:e1–e50.
15. Clinical and Laboratory Standards Institute. Reference method for broth microdilution antifungal susceptibility testing of yeasts. 4th informational supplement. CLSI M27-S4. Pennsylcania: Clinical and Laboratory Standards Institute; 2012.
16. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45:883–93.
17. Betts RF, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, Bedimo RJ, et al. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009;15;48:1676–84.
18. Kohno S, Izumikawa K, Yoshida M, Takesue Y, Oka S, Kamei K, et al. A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis. Eur J Clin Microbiol Infect Dis 2013;32:387–97.
19. Chow JK, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg DA, et al. Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med 2008;36:1993–8.
20. Wagner M, Bonhoeffer J, Erb TO, Glanzmann R, Häcker FM, Paulussen M, et al. Prospective study on central venous line associated bloodstream infections. Arch Dis Child 2011;96:827–31.
21. Eschenauer GA, Carver PL, Patel TS, Lin SW, Klinker KP, Pai MP, et al. Survival in Patients with Candida glabrata Bloodstream Infection Is Associated with Fluconazole Dose. Antimicrobial Agents and Chemotherapy 2018;62:e02566–17.
22. Karadag-Oncel E, Kara A, Ozsurekci Y, Arikan-Akdagli S, Cengiz AB, Ceyhan M, et al. Candidaemia in a paediatric centre and importance of central venous catheter removal. Mycoses 2015;58:140–8.